Due to the suspected death of six users, the intravenous human immunoglobulin produced by Jiangxi Boya Biopharmaceutical Co., Ltd. has been ordered to stop sales and use throughout the country. Yesterday, the State Food and Drug Administration stated that the China National Institute for the Control of Pharmaceutical and Biological Products had urgently tested samples taken from hospitals, operating companies, and manufacturing companies. Preliminary results showed that some samples were abnormal.
The public security department in Jiangxi Province has been involved in the investigation.
Jiangxi Boya Company issued a public statement yesterday, claiming that the number of problem drugs with lot number used by the deceased was 9,575, and 3,192 had already been used. The remaining 6,383 have been sealed and recalled, accounting for 67% of the total sales volume.
Cong Luoluo, deputy director of the Beijing Municipal Bureau of Food and Drug Control, told reporters yesterday: “The Beijing Municipal Food and Drug Administration started the emergency mechanism overnight and has now controlled all of its liberal arts products, but no batches of drugs have been found.â€
The public security department in Jiangxi Province has been involved in the investigation.
Jiangxi Boya Company issued a public statement yesterday, claiming that the number of problem drugs with lot number used by the deceased was 9,575, and 3,192 had already been used. The remaining 6,383 have been sealed and recalled, accounting for 67% of the total sales volume.
Cong Luoluo, deputy director of the Beijing Municipal Bureau of Food and Drug Control, told reporters yesterday: “The Beijing Municipal Food and Drug Administration started the emergency mechanism overnight and has now controlled all of its liberal arts products, but no batches of drugs have been found.â€